Company: MDXG
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001376339-25-000009
Chunk: 7

Company: MIMEDX GROUP, INC.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 8
Chunk 7
---
 (21,133)Cash and cash equivalents, beginning of period82,000 65,950 87,083 Cash and cash equivalents, end of period$104,416 $82,000 $65,950 See notes to the consolidated financial statements.

F- 7

MIMEDX GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(in thousands, except share data) Common StockAdditionalPaid-inTreasury StockAccumulated  SharesAmountCapitalSharesAmountDeficitTotalBalance at December 31, 2021112,703,926 $113 $165,695 778,710 $(4,017)$(161,709)$82 Share-based compensation expense— — 12,666 — — — 12,666 Exercise of stock options160,762 — (618)(151,239)1,269 — 651 Issuance of restricted stock840,759 1 (3,969)(882,251)3,968 — — Restricted stock shares canceled/forfeited— — 30 5,338 (30)— — Shares repurchased for tax withholding— — — 249,442 (1,190)— (1,190)Net loss— — — — — (30,197)(30,197)Balance at December 31, 2022113,705,447 $114 $173,804 — $— $(191,906)$(17,988)Share-based compensation expense— — 17,178 — — — 17,178 Employee stock purchase plan 444,809 — 1,367 — — — 1,367 Issuance of restricted stock2,185,604 2 (268)(73,335)266 — — Restricted stock shares canceled/forfeited— — 378 90,367 (378)— — Exercise of stock options130,129 — 885 (17,032)112 — 997 Repurchase of Series B Preferred Stock— — (4,935)— — — (4,935)Conversion of Series B Preferred Stock29,761,650 30 87